MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Organization & Developments: Bellicum
Parents
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Children
2011: Ariad Extends Three Tech Licensing Deals (2011)
2018: An Option Strategy For Bellicum Pharmaceuticals_seekingalpha.com
2018: Bellicum +18.3% as FDA lifts clinical hold on BPX-501 studies - Bellicum Pharmaceuticals (NASDAQ:BLCM)
2018: Bellicum Pharmaceuticals: Clinical Hold Addressable, Re-Adding To ROTY Contenders List_seekingalpha.com
2018: Bellicum reports first data on ‘controllable’ CAR-T
2018: Brain damage cases force an FDA hold on Bellicum’s lead cell therapy — shares tank – Endpoints News
2019: Bellicum Pharma +6.6% on Baker Bros. stake_seekingalpha.com
2019: Bellicum: Encouraging Data With A Discouraging Share Price_seekingalpha.com
2019: Bellicum: Oversold In 2018 And Undervalued In 2019_seekingalpha.com
2019: Bellicum: Still Discounted After MD Anderson Deal_seekingalpha.com
2019: Bellicum: Strong Trial Data, Poor Share Price, Dire Financials_seekingalpha.com
2020: Bellicum Pharmaceuticals: Accumulating At This Valuation
2020: Bellicum slashes 79% of staffers after early data quash hope around next-gen CAR-T
2021: Bellicum Pharmaceuticals: Narrowing The Thesis And Simplifying The Investment
Bellicum is implementing its branded Chemical Induction of Dimerization "CID" technology platform to engineer their product candidates with "switch" technologies that are planned to control mechanisms of the immune system
Bellicum Pharmaceuticals, Inc. is a clinical stage company developing therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases.
Industry: Pharmaceuticals / Drugs Sub-Industry: N/A
The company has been a focus of investor attention for its potentially safer CAR-T technology that incorporates a safety switch to control side effects like cytokine release syndrome
Jumps
*Key People: Bellicum
Finance & Acquisitions: Bellicum